Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0633 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Arm 1: Drug |
| Name | Type | Description |
|---|---|---|
| MK0633 | DRUG | Single dose MK0633 100mg po in the fed state administered during a 4-wk study. |
| Comparator: MK0633 | DRUG | A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight. |
Inclusion Criteria: * Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease * Inflammatory marker found in your blood, known as hsCRP \> 0.5 mg/L Exclusion Criteria: * Age \< 40 or \> 85 * Female * Heart attack, coronary artery bypass, stroke or...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
MK0633 is an investigational small molecule developed by Merck & Company, Inc. (MRK). It has been studied in clinical trials for asthma and atherosclerosis. MK0633 remains in clinical development and is not approved for any indication. The program's trials are all listed as completed, with no active studies currently recruiting.
MK0633 was studied in Phase 1 trials in asthmatic children, including single dose and plasma level studies in patients aged 6 to less than 16 years. It was also evaluated in a Phase 2 study in patients with atherosclerosis. MK0633 is investigational and has not been approved for treating asthma or any other condition.
MK0633 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the clinical trials of MK0633 in asthma and atherosclerosis. The drug remains an investigational asset in the company's pipeline rather than an approved commercial product.
MK0633 has been tested in Phase 1 and Phase 2 clinical trials. The Phase 1 studies were conducted in asthmatic children, while a Phase 2 study evaluated MK0633 in patients with atherosclerosis. All of these trials are completed, and no active trials are currently listed for MK0633.
MK0633 has been evaluated in completed trials including NCT00768170, a single dose study in Japanese asthmatic children aged 12 to less than 16 years; NCT00751413, which measured plasma levels in children ages 6 to 12; NCT00646789, a safety and tolerability study in asthmatic children; and NCT00421278, a Phase 2 atherosclerosis study.
Yes. MK0633 is also referred to as Comparator: MK0633. Both names refer to the same investigational small molecule developed by Merck & Company, Inc. (MRK) and studied in asthma and atherosclerosis trials.